THANK YOU FOR SUBSCRIBING
FREMONT, CA: Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the evolution, development, and leveraging of life-changing therapies to treat a wide range of rare and common diseases, announced today that it has initiated an underwritten-public-offering-of $250 million in common shares. Biohaven will offer all of the common shares for sale in the offering. Furthermore, Biohaven plans to provide the underwriter a thirty-day window during which to buy an additional $37.5 million of common shares at the price of the public offering, less fees and underwriting discounts.
For this deal, J.P. Morgan and Morgan Stanley are acting as book-running managers.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The offering is being made only by means of a prospectus supplement and the associate prospectus, copies of which, when available, may be acquired from the offices of J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.
The shares will be registered under an effective shelf registration statement on Form S-3. Before investing in the offering, interested parties should read the prospectus and corresponding prospectus supplement for this offering, as well as the records incorporated by reference and other documents filed by Biohaven with the Securities and Exchange Commission.
More in News